Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 3/20 | 0.70 |
| ▸ | NOS1 | P29475 | 3/20 | 0.70 |
| ▸ | NOS2 | P35228 | 3/20 | 0.70 |
| ▸ | SLC7A5 | Q01650 | 8/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.54 |
| ▸ | ALPI | P09923 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | XIAP | P98170 | 1/20 | 0.54 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.52 |
| ▸ | CASR | P41180 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | FYN | P06241 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL288850 | 1.00 | NOS3 (0.70) | NOS3NOS1NOS2SLC7A5PTGS1 | |
| SCHEMBL29589136 | 1.00 | NOS3 (0.70) | NOS3NOS1NOS2SLC7A5PTGS1 | |
| SCHEMBL7260682 | 1.00 | NOS3 (0.70) | NOS3NOS1NOS2SLC7A5PTGS1 | |
| SCHEMBL20715034 | 0.89 | NOS3 (0.59) | NOS3NOS1NOS2SLC7A5GRIA2 | |
| SCHEMBL6046229 | 0.87 | NOS3 (0.71) | NOS3NOS1NOS2SLC7A5PTGS1 | |
| SCHEMBL4629196 | 0.86 | NOS3 (0.53) | NOS3NOS1NOS2SLC7A5PTGS1 | |
| SCHEMBL3152192 | 0.85 | NOS3 (0.73) | NOS3NOS1NOS2SLC7A5PTGS1 | |
| SCHEMBL20502934 | 0.85 | NOS3 (0.73) | NOS3NOS1NOS2SLC7A5PTGS1 | |
| SCHEMBL20502933 | 0.85 | NOS3 (0.73) | NOS3NOS1NOS2SLC7A5PTGS1 | |
| SCHEMBL8075751 | 0.83 | NOS3 (0.50) | NOS3NOS1NOS2CASRITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017481-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2018-07-10 | — | — | US | claimed |
| EP-2836485-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2018-01-10 | — | — | EP | claimed |
| US-9695191-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2017-07-04 | — | — | US | claimed |
| EP-2499148-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2017-01-18 | — | — | EP | claimed |
| US-9512139-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2016-12-06 | — | — | US | claimed |
| US-20150051183-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2015-02-19 | — | — | US | claimed |
| EP-2836485-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | Polyphor Ag (CH) | 2015-02-18 | — | — | EP | claimed |
| EP-2462147-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2014-11-12 | — | — | EP | claimed |
| WO-2013139697-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2013-09-26 | — | — | WO | claimed |
| US-20120270881-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2012-10-25 | — | — | US | claimed |
| US-7659396-B2 | Method for the production of phenylalanine derivatives | WILEX AG (DE) | 2010-02-09 | — | — | US | claimed |
| US-20090005562-A1 | Method for the Production of Phenylalanine Derivatives | WILEX AG (DE) | 2009-01-01 | — | — | US | claimed |
| WO-2008107362-A2 | STABILISER AND INHIBITORS OF FACTOR VII | NOVO NORDISK HEALTH CARE AG (DK) | 2008-09-12 | — | — | WO | claimed |
| EP-1483285-B1 | INHIBITORS OF THE BLOOD-CLOTTING FACTOR Xa, PRODUCTION THEREOF AND USE OF THE SAME | CURACYTE AG (DE) | 2008-05-07 | — | — | EP | claimed |
| EP-1534283-B1 | FORMULATION OF LIPOSOMAL DERIVATIVES OF PHENYLALANINE | WILEX AG (DE) | 2005-12-14 | — | — | EP | claimed |
| US-20050245757-A1 | Method for the production of phenylalanine derivatives | WILEX AG (DE) | 2005-11-03 | — | — | US | claimed |
| US-20050181034-A1 | Formulation of liposomal derivatives of phenylalanine | WILEX AG (DE) | 2005-08-18 | — | — | US | claimed |
| US-20050119190-A1 | Inhibitors of the blood-clotting factor xa, production thereof and use of the same | CURACYTE AG (DE) | 2005-06-02 | — | — | US | claimed |
| EP-1483285-A1 | INHIBITORS OF THE BLOOD-CLOTTING FACTOR Xa, PRODUCTION THEREOF AND USE OF THE SAME | Curacyte AG (DE) | 2004-12-08 | — | — | EP | claimed |
| WO-2003076457-A1 | INHIBITORS OF THE BLOOD-CLOTTING FACTOR Xa, PRODUCTION THEREOF AND USE OF THE SAME | CURACYTE AG (DE) | 2003-09-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119190-A1 | Inhibitors of the blood-clotting factor xa, production thereof and use of the same | SERPINC1, TFPI, F11 | NOS3 2341/4885NOS1 2360/4885NOS2 3162/4885 |
| US-10017481-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | CTSE, CTSB, CTSS | NOS3 272/4885NOS1 818/4885NOS2 1302/4885 |
| US-20090005562-A1 | Method for the Production of Phenylalanine Derivatives | PAH, NPEPPS, DNPEP | NOS3 213/4885NOS1 989/4885NOS2 608/4885 |
| US-20050181034-A1 | Formulation of liposomal derivatives of phenylalanine | FAP, DNPEP, PLAU | NOS3 3312/4885NOS1 3937/4885NOS2 3701/4885 |
| US-20050245757-A1 | Method for the production of phenylalanine derivatives | PAH, NPEPPS, DNPEP | NOS3 213/4885NOS1 989/4885NOS2 608/4885 |
| US-20120270881-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | KCNB1, KCNAB1, KCNMB1 | NOS3 4340/4885NOS1 4492/4885NOS2 4750/4885 |
| US-20150051183-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | CTSE, CTSB, CTSS | NOS3 272/4885NOS1 818/4885NOS2 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.